ArticleBiomaterials and biosystems2026
Mentha-mediated selenium nanoparticles attenuate adriamycin-induced chronic kidney disease via multi-target modulation of oxidative, inflammatory, and fibrotic pathways.
Article in Biomaterials and biosystems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is characterized by progressive renal dysfunction associated with oxidative stress, inflammation, apoptosis, podocyte injury, and fibrotic remodeling. Adriamycin (ADR)-induced nephropathy is a widely used experimental model that reproduces key features of CKD, including proteinuria, glomerular and tubular injury, and renal fibrosis. Green-synthesized selenium nanoparticles (SeNPs) have emerged as potential renoprotective agents owing to their antioxidant activity and favorable biocompatibility. Objective: This study investigated the renoprotective efficacy of Mentha-mediated biosynthesized SeNPs against ADR-induced CKD in rats and explored the underlying molecular mechanisms. Methods: SeNPs were biosynthesized using sodium selenite and Mentha extract as reducing and capping agent. The synthesized nanoparticles were characterized by UV-visible spectroscopy, transmission electron microscopy (TEM), zeta size and zeta potential analysis, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FTIR). Eighteen male Sprague-Dawley rats were allocated into control, ADR-induced CKD, and ADR + SeNPs groups. At the end of the experimental period, renal function markers, oxidative stress parameters, proteinuria, histopathological alterations, alpha smooth muscle actin (α-SMA) immunoreactivity, and the mRNA expression of apoptotic, inflammatory, and fibrotic genes were assessed. Results: Characterization confirmed the formation of predominantly spherical SeNPs with a primary particle size of approximately 45-50 nm, a crystalline trigonal selenium structure, moderate colloidal stability, and surface functional groups consistent with biological capping. ADR administration caused significant renal dysfunction, increased urinary protein-to-creatinine ratio (UPCR), decreased renal Wilms tumor 1 (WT1) protein concentration, increased malondialdehyde (MDA), reduced superoxide dismutase (SOD) activity, severe histopathological damage. ADR also increased collagen deposition and α-SMA immunoreactivity and upregulation of Bax, p53, TNF-α, TGF-β, and Collagen-1 genes. SeNPs treatment improved serum renal-function parameters, significantly reduced UPCR, increased renal WT1 concentration, restored SOD activity, decreased MDA levels, and restored renal histoarchitecture. SeNPs also reduced α-SMA immunoreactivity, attenuated fibrotic alterations, and downregulated pro-apoptotic, pro-inflammatory, and pro-fibrotic gene expressions. Conclusion: Mentha-derived SeNPs effectively attenuated ADR-induced CKD through coordinated antioxidant, anti-inflammatory, anti-apoptotic, and anti-fibrotic actions. These findings highlight the therapeutic potential of green-synthesized SeNPs as a promising nano-based therapeutic approach for chronic renal injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.